Pre-processing algorithms and gene-selection methods play vital roles in the identification of Differentially Expressed Genes (DEGs) in microarray data as potential cancer biomarkers. Previous studies have established that different combinations of pre-processing algorithms and gene-selection methods have varying sensitivities for DEG identification. However, the impact of this variation in DEG identification has not been investigated at the interactome level. In this study, we evaluated eight different combinations of pre-processing algorithms and gene-selection methods for their ability to identify DEGs and prioritise relevant networks in the human cancer interactome. Our results illustrated that different combinations of algorithms yielded highly dissimilar gene-lists, yet all the gene-lists had similar abilities in segregating tumour samples from normal. An interactome analysis revealed that each gene-list prioritised different cancer-associated gene networks. Hence, the initial choice of a pre-processing algorithm and gene-selection method had a significant impact on the prioritisation of gene-networks most pertinent to carcinogenesis.
Introduction
Cancer is a complex disease that involves a sequence of stepwise processes characterised by accumulation of mutations, ultimately resulting in changes in gene expression profiles of cancer tissues. Although large population-based studies have provided important information concerning many of the complexities of gene interactions associated with these processes, prognostic and diagnostic gene signatures put forth by these studies have met with limited success in clinical applications (Subramanian and Simon, 2010 ). The lack of success of these gene signatures in clinical settings has been partly attributed to statistical issues such as limited sample sizes used in microarray investigations and over-fitting of classifier models (George, 2008) . However, even with increasing sample sizes in recent microarray studies, the development of robust gene signatures has been circumscribed by the identification of relevant Differentially Expressed Genes (DEGs) between cancer and normal phenotype, which are mined from the microarray data. The new paradigm for gene signature development is to utilise the growing knowledge on the cancer interactome for the identification of genes that are both biologically associated as well as statistically significant between the cancer and normal phenotypes (Huang et al., 2009) .
One of the main challenges in the utilisation of microarray technology is the effective removal of 'noise', or signal errors from the gene expression in the microarray data. These errors are often introduced inevitably during the microarray preparation and scanning process. This issue was partially resolved by the formation of the Microarray Quality Control Consortium (MAQC) in 2006, led by the US FDA and comprised of dozens of large research institutes and hospitals. In their landmark paper published in Nature Biotechnology, Peterson et al. (2006) dispelled the myth that microarray technology does not allow for re-producible results. The MAQC consortium instituted standards for the use of microarray technology, and this helped standardise all the protocols for microarray analysis prior to the digital microarray data files being produced. With the MAQC guidelines providing standardisation upstream of the creation of the digital data file, the focus shifted to the capabilities of the pre-processing algorithms and gene-selection methods in accurately determining gene expression and identifying DEGs.
All Affymetrix pre-processing algorithms are benchmarked for DEG identification accuracy using spike-in datasets prior to release (Cope et al., 2004 ) (spike-in datasets have a predetermined set of DEGs for identification). Accordingly, gene-selection methods are statistical methods carefully designed to detect such DEGs. However, the benchmark spike-in datasets were considered non-representative of complex disease datasets, as they had only several dozen DEGs, while complex diseases could potentially have thousands. To evaluate the different combinations of pre-processing algorithms and gene-selection methods for complex disease investigations, Choe et al. (2005) designed a spike-in dataset with 1309 DEGs. Choe's study found that there were clear differences in the sensitivity and specificity of DEG detection among the different processing pairs. Their study estimated a maximum sensitivity of approximately 70% for DEG detection across all the different combinations of pre-processing algorithms and gene-selection methods studied. Sensitivity in this context was defined as the total percentage of true positives that could be reliably detected before the false-positive rate exceeds 10%. A similar finding was reported by Harr and Schlötterer in their study, which favoured the use of natural biological systems over spike-in datasets (Harr and Schlötterer, 2006) .
In this study, we evaluated the impact of the variation in DEG detection due to differences in sensitivity for eight different combinations of pre-processing algorithms and gene-selection methods on a single Hepatocellular Carcinoma (HCC) microarray dataset. The eight combinations of algorithms were evaluated on their ability to generate gene signatures as well as enrich gene-networks that were relevant to the disease biology being studied. Four pre-processing algorithms (MAS, RMA, GCRMA and PLIER) were combined with two gene-selection methods (Double-Filtering and Significance Analysis of Microarrays) to generate the eight different combinations. We demonstrated that the eight different combinations of algorithms, when applied to the HCC dataset, yielded gene-lists that were highly different from each other. However, when the top-100 ranked genes within each of the eight gene lists were utilised as a gene-signature, all the eight gene signatures had similar abilities in segregating tumour samples from normal. The ability of the eight signatures to segregate tumour samples from normal was further validated on an independent microarray HCC dataset. Interactome analysis revealed that the gene-lists from the eight different combinations of algorithms prioritised different cancer-associated gene networks. Hence, the initial choice of a pre-processing algorithm and gene-selection method had a significant impact in the prioritisation of gene networks most pertinent to carcinogenesis and the subsequent selection of biologically correlated genes for use in gene-signatures.
Materials and methods

Microarray technology and computation of gene expression
Once the Affymetrix™ scanner had processed the GeneChip ® (used to investigate the sample of interest), a digital file called the CEL file was created. This CEL file was processed by the four pre-processing algorithms to generate the final 22,215 gene expression values (for the HG-U133A chip) for each sample. The CEL file is actually a data matrix with each cell location representing a gene probe intensity value. A gene is targeted by a total of 22 probes organised into 11 probe-pairs, collectively called a probeset. Each probe-pair consists of a Perfect Match (PM) probe and a Mis-Match (MM) probe. The 11 PM probes together form a sequence that is matched to the gene being investigated. The MM probes are an exact replica of the PM probes except for the thirteenth base-pair, which is a nucleotide mismatch to the target gene. In summary, 11 PM probes together constitute the response signal, 11 MM probes together constitute an error signal and the 22 probes together constitute the probeset that targets a specific gene. Multiple different probesets can also target the same gene. The gene detection concept can hence be presented as the following equation.
The purpose of all the pre-processing algorithms evaluated in this paper can be summarised simply as the capability to differentiate the biological signal from the error. Although on the surface this looks simple, in practical terms there are complex situations arising from the error signal being a combination of both systemic and non-systemic errors. We have modelled the gene expression computation equation in generic terms, using all the information provided by the four pre-processing algorithms, so as to facilitate comparison between the four pre-processing algorithms. All the values are of type (scalar, float) and are presented in log scale, which is a standard practice for working with gene expression data.
The terms are defined as follows
• C R : Computed response -The final gene expression value calculated by the pre-processing algorithms and used by the researcher in the investigations.
• F R : Feature response -The final value computed by the summarisation of the 11 PM probes.
• F E : Feature error -The final value computed by the summarisation of the 11 MM probes.
• SB E : Systemic background error -The level of systemic (invariant) error that occurs in the background due to the microarray preparation process.
Equation (2) provides an overview of the required computation of the gene expression value and its associated complexity. Each of the four pre-processing algorithms has computationally different implementations for equation (2). In our experiment, we would show that this implementation difference has a significant impact on the subsequent detection of DEGs.
Pre-processing algorithms
We choose four established algorithms for our initial investigations: MAS5 (Hubbell et al., 2002) , RMA (Irizarry et al., 2003) , GCRMA (Wu et al., 2004) and PLIER (Affymetrix, 2005) . The selection of algorithms was based on the research by Choe and Harr described in the Introduction. The authors utilised MAS5, RMA and GCRMA, described previously, as well as the Li-Wong algorithm (Li and Hung Wong, 2001) . However to limit the number of factors that could potentially influence the outcome of the investigation, we decided to standardise all the pre-processing of the CEL files on the R statistical environment (www.R-project.org). As the Li-Wong algorithm did not have a native implementation in R, we substituted it with PLIER, based on the paper by Gyorffy et al. (2009) where the authors indicated that PLIER had superior concordance with real-time PCR data as compared to seven other pre-processing algorithms.
The MAS algorithms were developed by Affymetrix™ as part of their microarray suite of software tools for the analysis of GeneChip© CEL files. The vs. 5 that is evaluated in this paper was presented by Hubbell et al. (2002) . MAS5 uses the Tukey Biweight robust estimator for the computation of F R and F E . In instances where the F E signal was greater than the F R signal, C R was set to 1. This was required for the log transformation, as log of a negative number would give an error. SB E was computed based on the Tukey Biweight mean signal of the lowest 2% of all probesets.
The Robust Multi-Array Average (RMA) algorithm was published by Irizarry et al. (2003) of John Hopkins University in 2002. Instead of calculating the gene expression levels individually per chip, the authors used the knowledge that multiple microarrays improve statistical power to use multi-array analyses to reduce error and compute a more accurate signal value for the target gene. To facilitate this process, they use quantile normalisation to first normalise all the expression values across the different arrays to a reference distribution. Subsequently for error correction, the authors have argued that the manner in which the MM probe signal grows with the PM probe signal often creates situations where the MM probe signal is greater than the PM probe signal. This can happen when non-specific hybridisation to the MM probe is higher than specific hybridisation to the PM probe. Their solution to the problem was to refrain from using the MM probes altogether, and to use a new convolution model to calculate the global background error, which is then subtracted from the PM signal to provide the final response. Hence, F E and SB E are effectively merged into a single entity, which was computed from the convolution model. The F R value was computed using the Median-Polish method.
The GCRMA (G-C content adjusted RMA) algorithm was proposed by Zhijin Wu in 2003 (Wu and Irizarry, 2005) . Zhijin states that by ignoring the MM intensities and using a global background adjustment step, RMA was able to sacrifice some amount of accuracy for larger gains in detection ability. However, the authors indicate that the loss of accuracy can be compensated if adjustments are made for non-specific hybridisation. It has been observed in other hybridisation techniques that if the G-C content in a sequence was high, there was a lot more non-specific hybridisation. The authors tested this concept in the microarray technology by grouping together MM probes with similar G-C content. The authors discovered that the intensity of the signals grew proportionally with increasing G-C content on the MM probes. Hence, the authors proposed that MM probes with similar G-C content be grouped together and be considered as pseudo-MM probes. These pseudo-MM probes are then matched to all PM probes with the same or similar G-C content. The use of this technique allowed for greater reliability in the estimation of non-specific binding and in the correction of F E and SB E. In all other aspects, GCRMA followed the RMA methodology exactly with the use of quantile normalisation and median-polish.
The Probe Logarithmic Intensity Error (PLIER) method was developed by Affymetrix™, Inc. (Santa Clara, CA), based on their original work on the MAS5 algorithm as well as on developments in the field of microarray data analysis till the year 2004. A comprehensive paper (Affymetrix, 2005) was released as a technical note on the Affymetrix™ website. The PLIER model is based on the premise that error is proportional to the intensity of the signal and not just the background. This effectively means that F E is the same as SB E at low intensities and F E is proportional to F R at high intensities. The capability to compute different values for F E is achieved using a unique dynamic weighting system which examines the 11 PM and 11 MM probes that comprise a probeset. The 22 probes (11 PM and 11 MM) have different responses to the target gene, varying from weakly responsive to moderately responsive to strongly responsive. Strongly responsive probes are informative at the low end, but saturate at the high end.
Weakly responsive features are uninformative at the low end, but are informative at the high end of the signal range. Based on these findings, the F R and F E values are computed by down-weighting some probes and up-weighting others prior to final computation. Once the C R values had been computed, quantile normalisation is used to improve the comparison of values across the different microarrays.
We have briefly described the main computational methodologies of the four pre-processing algorithms to highlight the extent of variation that exists between these pre-processing algorithms in the computation of C R , the final gene expression value.
Gene-selection methods
The Double-Filtering (DF) method uses two statistical measures to control the error rate in determining DEGs; the False Discovery Rate (FDR) and the Fold-Change. The t-test and p-value were designed to test a single hypothesis on a group of samples taken from the sample population. However, in microarray gene investigations, we test tens of thousands of hypothesis (genes) on the exact same set of samples. Hence, the field of multiple testing extends the single hypothesis testing computations so that the experiment-wide error rate can be controlled at an acceptable value while maximising the power of each test. The FDR is computed by conducting a multiple-testing correction such as the Benjamini and Hochberg procedure (Hochberg and Benjamini, 1990) or Storey's q-value (Storey and Tibshirani, 2003) on the p-value obtained after conducting a Student's t-test on a particular factor (e.g., histology). In this project, we utilise Storey's multiple testing correction (q-value). Fold-change is simply the ratio of the mean of gene expression of one group over the mean of another. For example, the fold-change for gene x between cancer and normal samples is the mean value of gene x in cancer samples divided by the mean value of gene x in normal samples. In general, higher fold-changes are more indicative of true biological differences, as this shows gene expression levels differ more significantly between the two states.
The Significance Analysis of Microarrays (SAM) technique, developed by Tusher, Tibshirani and Chu (Tusher et al., 2001) of Stanford University, was published in PNAS in April 2001. Since then, there has been continued work on the algorithm, and a new version was released in January 2007. The primary weaknesses identified by the authors in the double-filtering procedure were in the areas of fold-change detection and the assumption that all genes in the data follow a common distribution and hence, are treatable under the parametric tests. The authors discovered that the signal-to-noise ratio of a gene (which determines its capacity to be accurately detected) decreased with decreasing gene expression. In addition, variances in expression were gene-specific and were significantly different between high expression genes and low expression genes. Hence, low expression genes were highly likely to have a different gene expression distribution as compared to high expression genes, making parametric tests more error-prone when applied without taking this factor into consideration. The second shortcoming was in the area of fold-change detection. As the signal-to-noise ratio is lower for low expression genes, it is statistically likely that 2-fold changes may occur at random for a large number of genes in this category. Conversely, for higher levels of expression, smaller changes in gene expression (less than 2-fold) would be rejected by double-filtering methods, but in actuality, are more real in representing biological expression. To overcome these issues, the authors developed the SAM score, which is based on the ratio of change of gene expression of a particular gene to the standard deviation in the data for that gene over repeated permutations of the dataset using a resampling method.
Principal Component Analysis (PCA) and batch effects removal
In this study, we were trying to differentiate between patients with cancerous tumour and normal patients, using the top 100-ranked probesets. Hence, each patient is described by 100 features and yet, one cannot visualise beyond 3 dimensions. By reducing the structure of high-dimensional data to lower dimensions (i.e., from 100 to 3), PCA allows for the visualisation of the high dimensional data in the study. The criteria for the segregation of the tumour samples from normal, was that there must exist a clearly defined separation between tumour samples and normal samples in the PCA and any sample overlap between the 2 groups must be less than or equal to 10% of the total sample size. In addition, the PCA must capture at least 80% of all variance in the dataset. While further validation using a gene classifier such as a discriminant analysis could be performed, we omitted this step, as the purpose of our experiment in this context was simply to establish the validity of the probesets and the corresponding gene-signature that could be derived. If PCA analysis had already indicated a very high potential for segregation of tumour and normal samples, we were confident that any additional gene classifiers would perform as well, if not better.
An additional aspect of pre-processing of the data is in the removal of systematic biases in the data, called 'batch effects' (Leek et al., 2010) . Batch effects are commonly introduced by microarray chips that are scanned in separate batches. Upon analysis of the data, it was found that the data tend to cluster around the batch factors instead of the clinical factors, causing the data to be incomparable. For this study, we used the batch effect removal provided by the Partek ® software, vs. 6.4, which allows for the batch removed data to be available as a spreadsheet.
Experiment workflow
Figure 1 presents all the experimental steps which were employed to process the microarray data using the different combinations of the four pre-processing algorithms and two gene-selection methods. The top 100-ranked probesets were identified for each combination of a pre-processing algorithm with a gene-selection method, and subsequently used for a comparative study of gene profiles and gene networks. 
Hepatocellular Carcinoma datasets
Hepatocellular Carcinoma (HCC) is a form of primary cancer of the liver, and is known to be a highly malignant cancer, often resulting in a poor outcome for the patient. Worldwide, HCC has been attributed to over 500,000 cancer-related deaths annually. The primary HCC dataset used in this study has been reported previously by Wang et al. (2007) , Liu et al. (2008) . The microarray hybridisation was done on Affymetrix™ HG-U133A and HG-U133B gene chips. For this report, only the HG-U133A chip was used. A total of 39 CEL files generated from tumour samples and 26 CEL files from normal samples were used in this investigation. The dataset is publicly available through ArrayExpress, accession numbers E-MEXP-84 and E-TABM-292. We employed another comparable and independent HCC dataset (Deng et al., 2010) from the University of Tokyo for validation of our results. The HCC dataset comprises of 10 HCC tumour samples and 10 matched-normal samples, and is publicly available from Gene Expression Omnibus using the accession number GSE19665. While there were several dozen datasets on GEO and ArrayExpress that we shortlisted as potential datasets for validation purposes, only Deng's dataset was matched to our primary dataset, based on several important parameters such as the Affymetrix platform, availability of patient tumour samples expressing the hepatitis B strain (the dominant strain in our primary HCC dataset) and the availability of both tumour samples and normal samples in the same experiment.
Heatmap analysis
Heatmap analysis has been used extensively for the investigation of consensus across the top-ranked probeset lists generated by the different combinations of pre-processing algorithms and gene-selection methods. The heatmap is a visual representation of a binary table; columns represented a probeset in the combined probeset list, while rows represented the different pre-processing algorithms. For any given row by column position, the value would be either one or zero. A value of one would indicate that the algorithm (row) had detected that particular probeset (column) within its top 100-ranked probeset list. In contrast, a value of zero indicated the absence of that probeset in the top 100-ranked probeset list. The Partek ® software was utilised to colour-code; red indicated presence (detected) and blue indicated absence (not detected).
Results
Identification of top 100-ranked probesets for the 4 pre-processing algorithms using the double-filtering method
The following tests were performed on the four gene expression spreadsheets between the tumour and normal samples; t-test, multiple-test correction using Storey's q-value and fold-change calculation. Based on the DF procedure explained previously, probeset lists were generated using a series of different statistical criteria. The criteria for selection and the number of probesets that passed the given criteria are shown in Table 1 . Table 1 demonstrates clearly that the number of probesets that passed the lowest significance criteria (q ≤ 0.0001 & FC ≥ |2|) as well as the highest significance criteria (q ≤ 0.0001 & FC ≥ |9|), differed substantially between the four pre-processing algorithms. Although the exact same dataset was processed by the four pre-processing algorithms, their identification and prioritisation of DEGs between tumour and normal samples was very different. We subsequently selected the top 100-ranked probesets within each prioritised probeset list for further investigation of the level of consensus between the probesets lists.
Table 1
A list of selection criteria based on FDR q-value and fold-change and the number of probesets that passed the selection criteria for each pre-processing algorithm. The values in bold showed the occurrence of the top 100-ranked probesets 
Heatmap analysis of the combined probeset list generated using DF
All the top 100-ranked probesets identified by the 4 pre-processing algorithms were combined to give a total of 414 probesets [GCRMA (100) + RMA (104) + PLIER (107) + MAS5 (103)]. Subsequently, removal of duplicate probesets resulted in a final list of 220 probesets. We utilised heatmap analysis to investigate the consensus amongst the four pre-processing algorithms (Figure 2 ). Analysis of Figure 2 revealed that only 31 out of 220 top 100-ranked probesets were prioritised as significant by all the 4 pre-processing algorithms, yielding a consensus of only 14%.
Figure 2
Heatmap analysis of the combined 220 top 100-ranked probesets from the 4 pre-processing algorithms combined with the DF method. Each column represents a probeset and each row represents a pre-processing algorithm. Red indicates presence of the probeset within the top 100-ranked probeset list of that pre-processing algorithm, while blue indicates absence of the probeset (see online version for colours)
PCA of the top 100-ranked probesets for each combination of a pre-processing algorithm with DF
PCA was performed using the top 100-ranked probesets generated from each of the 4 pre-processing algorithms combined with DF, to determine if the probesets were good classifiers of the tumour and normal samples. As seen in Figure 3 , the tumour and normal samples were perfectly separated, with zero overlap of samples. Hence, the probesets selected were highly representative of the true molecular patterns inherent in the tumour and normal samples. The most important finding was that the low consensus amongst the probesets discovered in Figure 2 , did not have any fundamental impact on the development of relevant gene-signatures to segregate tumour samples from normal samples utilising the different combinations of pre-processing algorithms with DF. Figure 3 PCA analysis for the segregation of the 65 patient samples into tumour and normal, using the top 100-ranked probesets for each combination of the 4 pre-processing algorithms with the DF method. The exact number of probesets used for each pre-processing algorithm is indicated in brackets ( ), followed by the criteria at which the selection was made
Identification of top 100-ranked probesets for the 4 pre-processing algorithms using SAM
Similar to the procedure used in Section 3.1, probeset lists were generated using a series of scaling SAM criteria, as shown in Table 2 . The number of probesets that passed the lowest significance criteria and the highest significance criteria continued to differ substantially across the four pre-processing algorithms. This result was strikingly similar to the result obtained from the DF method (Table 1) . We subsequently selected the top 100-ranked probesets within each prioritised probeset list for further investigation. 
Heatmap analysis of the combined probeset list generated using SAM
We combined the 4 top-100 ranked probeset lists from SAM and obtained a probeset list comprising of 411 probesets [MAS5 (136) + RMA (99) + GCRMA (105) + PLIER (71)]. Removal of duplicate genes yielded a final set of 231 probesets. Consensus amongst the 4 pre-processing algorithms for their top 100-ranked probesets selected by the SAM method was investigated using heatmap analysis (Figure 4) . Analysis of the data in Figure 4 showed that only 21 out of 231 genes were detected by all 4 pre-processing algorithms, yielding a consensus of only 9%. This number is comparatively smaller than the 14% consensus obtained for the DF selection method.
Figure 4
Heatmap analysis of the combined 231 top 100-ranked probesets from the 4 pre-processing algorithms combined with the SAM method. Each column represents a probeset and each row represents a pre-processing algorithm. Red indicates presence of the probeset within the top 100-ranked probeset list of that pre-processing algorithm, while blue indicates absence of the probeset (see online version for colours)
3.6 PCA of the top 100-ranked probesets for each combination of a pre-processing algorithm with SAM PCA was performed for the top 100-ranked probesets generated from the SAM selection process for each of the four pre-processing algorithms. As can be seen from Figure 5 , tumour and normal samples are perfectly separated, with zero overlapping of samples. Hence, once again the probesets selected can be regarded as highly representative of the molecular patterns inherent within the tumour and normal samples. It was noted by us that the separation of the two classes of samples is more pronounced in the SAM method ( Figure 5 ) as compared to the DF method ( Figure 3) . However, without a qualitative analysis of the probesets detected by each method, it is not possible to draw an inference as to whether the SAM method has a superior selection process. For the purposes of this study, we needed only a validated probeset list to perform the consensus investigation, and as both methods could differentiate the samples with 100% accuracy, we did not investigate further into the quality of probesets detected.
Figure 5 PCA analysis for the segregation of the 65 patient samples into tumour and normal, using the top 100-ranked probesets for each combination of the 4 pre-processing algorithms with the SAM method. The exact number of probesets used for each pre-processing algorithm is indicated in brackets ( ), followed by the criteria at which the selection was made
Validation of results on an independent HCC microarray dataset
The entire experimental workflow reported in Figure 1 was repeated on Deng's HCC dataset. The top 100-ranked probesets from each pre-processing algorithm combined with the DF method were used for PCA. There was a clear separation of the tumour samples from the normal samples, with no overlap. Similar results were obtained using the top 100-ranked probesets from each pre-processing algorithm combined with the SAM method (Figures for PCA were not shown). The top 100-ranked probesets from the 4 pre-processing algorithms combined with the DF method were then pooled together to create a combined probeset list. Similarly, a combined probeset list was created from the top 100-ranked probesets from the 4 pre-processing algorithms combined with the SAM method. The combined probeset lists were used for heatmap analysis and the results are shown in Figure 6 . Figure 6 shows that for the DF method, 22 of 216 top 100-ranked probesets were in consensus (10%). This was comparable to the 14% consensus seen in the NCC HCC dataset (Figure 2) . As for the SAM method, 20 of 215 top 100-ranked probesets were in consensus (9%) which was exactly the same as the consensus in the primary HCC dataset ( Figure 5 ). The results from the independent validation dataset showed that the lack of consensus discovered in the primary HCC dataset was not dataset-specific, but an outcome of the intrinsic variances in the computational methodologies of the pre-processing algorithms and gene-selection methods.
Figure 6
Heatmap analysis of the 216 top 100-ranked probesets from the 4 pre-processing algorithms combined with the DF method and the 215 top 100-ranked probesets from the 4 pre-processing algorithms combined with the SAM method for the independent HCC validation dataset (see online version for colours)
Impact of lack of consensus on gene network investigations
To ascertain the biological impact of the lack of consensus in DEG prioritisation by the different combinations of pre-processing algorithms and gene-selection methods, we uploaded the top 100-ranked probeset list from each of the 8 combinations of algorithms into the Ingenuity ® Pathway Analysis (IPA). The eight probeset lists (four using DF method and four using SAM method) were then utilised by IPA to build gene networks. Gene networks provide an overview of genetic interaction between the various genes in the network. Groups of interacting genes can then be investigated further to determine if they are involved in specific pathways, such as signalling cascades, cell cycle progression, apoptosis and so forth. Such biologically correlated genes are the potential choices for use in the development of gene signatures that are more representative of the disease biology. Two important networks were selected and presented in Figure 7 to investigate the impact of the lack of consensus on the genomic investigation of HCC. Network-A in Figure 7 consists of important genes such as CDK1, CDC25A (cell cycle progression, cancer), CXCL2 (chemokine, cancer) and FOS (cell proliferation, transformation, cancer) . Within the DF method, 32 out of the 39 genes in the network (82%) were detected in the top 100-ranked probeset lists of the 4 pre-processing algorithms. However, all the 32 genes were picked up by individual pre-processing algorithms, with no overlap in detection across different pre-processing algorithms. Within the SAM method, 11 out of the 39 genes (28%) were detected in the top 100-ranked probeset lists of the 4 pre-processing algorithms, again with no overlap in detection across the different pre-processing algorithms. Hence, Network-A is far more sensitive to detection using DF as compared to SAM.
Figure 7
Two gene networks detected by IPA based on the 8 top 100-ranked probeset lists that were analysed. Networks A and B were selected amongst the various options because of the large number of genes within the pathway that were detected by a single combination of a pre-processing algorithm and gene-selection method. The values in brackets (X/Y) are as follows: X -number of genes within the network that was detected within the top 100-ranked probeset lists of the 4 pre-processing algorithms; Y -Total number of genes within the network (see online version for colours) Network-B in Figure 7 depicts an equally important network with genes such as IGF1 (growth factor, cancer), CDK1, CENPF (cell cycle progression, cancer), MCM2 (chromosomal replication, cancer) and MT1F/X (cell morphology, cancer). Within the DF method, the 4 pre-processing algorithms detected 10 out of 50 genes in the network (20%) within their top 100-ranked probeset lists. Only 1 out of those 10 genes was detected by more than a single pre-processing algorithm. AGA Phosphotransferase was detected by both MAS5 and PLIER. All the other nine genes were detected by a single pre-processing algorithm only. For the SAM method, 42 out of the 50 genes (84%) were detected by the 4 pre-processing algorithms, indicating that Network-B is far more sensitive to detection by SAM as compared to detection by DF. However, out of the 42 genes detected, only 3 were detected by more than a single pre-processing algorithm.
Discussion
With the limited success of cancer gene signatures in being adopted into clinical practice (Subramanian and Simon, 2010) , the current paradigm in gene-signature development has been the study of the cancer interactome, to identify and select DEGs that are both biologically correlated as well as statistically significant. However, different combinations of pre-processing algorithms and gene-selection methods had been shown to have varying sensitivities in DEG identification (Choe et al., 2005; Harr and Schlötterer, 2006) . In this paper, we have examined the presence of potential intrinsic variances between different combinations of pre-processing algorithms and gene-selection methods and the ability of the top-ranked probesets derived from such combinations in interrogating a HCC microarray dataset. Table 1 and Table 2 illustrated that the 8 combinations of pre-processing algorithms and gene-selection methods interrogated the same HCC dataset with significant differences, as indicated by the occurrence of the top 100-ranked probeset list at differing gene-selection criteria. The rationale for the selection of the top 100-ranked probesets was twofold. First, the investigation of the impact of the probeset-list on gene profiling and gene network development required a small but representative gene-list. Second, gene profiles, which had been used for prognostic and diagnostic purposes, have in general not exceeded 100 genes in size. The observation of RMA with DF detecting all probesets at lowered selection criteria when compared to the other pre-processing algorithms is attributed to its fold-change compression issue (Cope et al., 2004) . This disparity in prioritisation of DEGs demonstrated by the eight combinations of algorithms is indicative of fundamental differences in their methodologies, as highlighted in Sections 2.2 and 2.3.
Heatmap Analysis (Figures 2 and 4) illustrated clearly that the consensus of the top 100-ranked probesets prioritised by the 4 DF combinations and 4 SAM combinations were very low (14% and 9% consensus respectively). However, although the heatmap results show a significant lack of consensus for the top 100-ranked probeset prioritisation, the top 100-ranked probeset list from each of the 8 combinations of pre-processing algorithms and gene-selection methods had been shown to have excellent results in segregating tumour samples from normal samples using PCA (Figures 3 and 5 ). To ensure that the results obtained from our study were not specific for the HCC microarray dataset that we employed, another comparable and independent HCC dataset from the University of Tokyo was employed to validate our findings, and the validation indicated similar results ( Figure 6 ). The issue of this probeset prioritisation variability and its impact on gene signature development was also studied in eight different microarray breast cancer datasets (Sontrop et al., 2009) . The authors reported that probeset prioritisation, which they termed 'feature variability', had a significant impact on the development of gene signatures. However, the lack of consensus in probeset prioritisation, both in our current study as well as the study by Sontrop et al. showed little impact on the development of comprehensive gene signatures capable of segregating the cancer and normal phenotypes using the different combinations of pre-processing algorithms and gene-selection methods.
While the lack of consensus was not an issue for gene signature development, the study of the interactome, however, could have been affected due to the necessity for the interactome analysis requiring a comprehensive and accurate overview of gene interactions. Figure 7 demonstrated that different combinations of pre-processing algorithms and gene-selection methods were able to detect only limited aspects of two important networks. In addition, many important cancer associated genes, such as IGF1, CXCL2, FOS, MCM2, CDK1, MT1F/X and others, were detected by only a single or at most two combinations of algorithms out of the eight combinations of pre-processing algorithms and gene-selection methods studied. It was only when all the probeset lists were combined that a clear representation of the gene network could be deciphered.
Many reports in the literature have utilised the methodology of developing probeset lists using an individual combination of a pre-processing algorithm with a gene-selection method, primarily to enable the accurate segregation of tumour from normal. However, the development of a clinically successful prognostic or diagnostic signature requires more than an assorted set of DEGs selected due to their statistical significance. More importantly, an understanding of the complex biological interactions between these DEGs in the context of cancer-specific pathways is required (Baudot et al., 2009) . By uploading the eight probeset lists identified with different pre-processing algorithms and gene-selection methods with the NCC HCC dataset into IPA to perform network analysis, we demonstrated clearly that biologically relevant genes within the cancer-specific pathways would have been missed if the conventional approach of using a single pre-processing algorithm with a gene-selection method was employed.
Conclusion
Our present study highlights the impact of the limited consensus of probesets prioritised by different combinations of pre-processing algorithms and gene-selection methods utilised to mine a single HCC microarray dataset and the subsequent impact of this lack of consensus on gene-signature and gene-network development. The traditional methodology for gene-signature development utilised an assorted set of genes that were selected due to their high statistical significance between cancer and normal phenotypes. However, these selected genes had little or no biological correlation with each other. Such gene-signatures have had limited success for predicting treatment outcomes in clinical oncology. The new paradigm is to select genes with both statistical significance as well as biological correlation. In our study, we demonstrated that the traditional methodology of using a single combination of a pre-processing algorithm with a gene-selection method could detect only aspects of the cancer interactome, and that different combinations of algorithms were detecting different groups of interacting genes. The development of a gene-signature with a set of biologically correlated genes was, hence, impacted by the initial choice of the pre-processing algorithm and gene-selection method employed by the investigator. However, no single combination of a pre-processing algorithm and gene-selection method could comprehensively enrich the cancer interactome. An approach that leverages multiple pre-processing algorithms and gene-selection methods may offer a better strategy in identifying functionally relevant molecular signatures that can potentially provide a comprehensive overview of the complex biological system being studied.
